The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Proxygen Snags Third Big Pharma Partner in Deal Valued at $2.55B 4/5/2023

AstraZeneca’s Imfinzi/Lynparza Combo Boosts Survival in Ovarian Cancer 4/5/2023

FDA Grants EUA to InflaRx’s Anti-Inflammatory COVID-19 Treatment 4/5/2023

How to Negotiate a Relocation Package: a Complete Guide 4/5/2023

A new Nature Immunology study led by University of Pittsburgh and National Institutes of Health researchers sheds light on how a rare type of helper T cell, called Th9, can drive allergic disease, suggesting new precision medicine approaches to treating allergies in patients with high levels of Th9.

Gene-editing therapy aimed at two targets - HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells - can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows. The study, published online in the journal The Proceedings of the National Academy of Sciences (PNAS), is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

19 - 20 June 2023, London, UK.
SAE Media Group is proud to announce the inaugural Cell and Gene Therapy Conference. As part of SAE Media Group's leading series of drug discovery conferences, this year's event will bring together expertise from individuals across the advanced therapeutics community. The two-day conference will offer a series of presentations, through which delegates will gain insight into the latest developments in discovery, development and delivery of cell and gene therapies.

Humira Sales Down 25% as AbbVie Cuts Two Programs 4/28/2023

FDA Greenlights Pfizer’s Pneumococcal Vaccine in Infants and Children 4/28/2023

Lilly’s Mounjaro Poised to Challenge Novo’s Wegovy in Obesity 4/28/2023

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®.

The University of Cincinnati's Soma Sengupta, MD, PhD, published an article in the Journal of Neuro-Oncology April 25 discussing her journey and approach to practicing integrative neuro-oncology.

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist,

Beam Spin-Out Orbital Therapeutics Raises $270M to Advance RNA Portfolio 4/26/2023

Biogen Bets on Anticipated Approvals Amidst Pipeline Reprioritization 4/26/2023

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas 4/26/2023

US Senate Kicks Off Fresh Round of Drug Pricing Control Legislation 4/26/2023